Trial Profile
A Randomized Patient -Blind Controlled Phase III Study to Compare the Efficacy and Safety of Intravenous Ferric Carboxymaltose (Ferinject) With Placebo in Patients With Acute Isovolemic Anemia After Gastrectomy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ferric carboxymaltose (Primary)
- Indications Iron deficiency anaemia
- Focus Therapeutic Use
- Acronyms FAIRY
- 23 May 2017 Results published in the JAMA: the Journal of the American Medical Association
- 19 Oct 2016 Primary endpoint of number of responders has been met, according to results presented at the 24th United European Gastroenterology Week.
- 19 Oct 2016 Results presented at the 24th United European Gastroenterology Week